In a study of perinatally infected teens in Cameroon with failed ART, 27% of patients had drug resistance mutations in their proviral DNA that were not detected in plasma RNA.
Adolescents with HIV infection acquired through vertical transmission (e.g., perinatally) present treatment challenges for many reasons, including drug resistance mutations (DRMs) that accumulate during sequential changes in their antiretroviral therapy (ART) regimens. DRMs related to failed previous regimens may not be detected with plasma viral RNA genotyping during subsequent regimens, but proviral DNA found in cellular reservoirs (such as CD4 cells) represents a source of archived DRMs. Investigators in Cameroon assessed HIV-1 resistance testing in plasma RNA versus proviral DNA samples from vertically infected teens (mean age, 16) failing their current ART regimen (defined as plasma HIV RNA >1000 copies/mL). Among 296 eligible particip…
Reviewing Author
DisclosuresConsultant/Advisory BoardViiV Advisory Board
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardViiV Advisory Board
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes